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Introduction: More data are essential to test the efficacy of the sev-
enth edition of the American Joint Committee on Cancer (AJCC) 
staging system for esophageal squamous cell carcinoma (ESCC). 
This retrospective study was designed to identify the prognostic 
factors for survival of patients with ESCC who underwent surgical 
resection alone and to evaluate the new AJCC staging system for 
ESCC.
Methods: Data of a single-center cohort of 2011 patients with ESCC 
who underwent surgical resection alone according to the new stag-
ing system were reviewed. Univariate and multivariate analyses were 
performed to identify prognostic factors.
Results: The 1-, 3-, and 5-year overall survival rates were 83.5, 
57.4, and 47.4%, respectively, with a median survival time of 51.0 
months. Age, histologic grade, R-category, pT category, pN cat-
egory, pM category, pTNM stage, and the extent of lymph node 
metastasis were independent prognostic factors (p < 0.05). In sepa-
rate subgroup analyses, the survival differences were not significant 
for pN2 versus pN3 category (p = 0.159) and stages IA versus IB 
(p = 0.922). Subdivisions by depth of infiltration rather than tumor 
grade for pT1N0M0 cancers and modified nodal categories (0, 1, 
2–3, and ≥4 positive lymph nodes) better represented a survival 
advantage.
Conclusions: The seventh edition of the AJCC staging system for 
ESCC is acceptable in predicting survival. However, tumor location 
does not influence survival in our study. Subdivisions of pT1N0M0 
cancers and the N-classification may need to be modified.
Key Words: Cancer staging, Esophageal squamous cell carcinoma, 
Prognosis, Survival
(J Thorac Oncol. 2013;8:495-501)
The seventh edition of the American Joint Committee on Cancer (AJCC) staging system for esophageal cancer was 
published in January 2010. A database of 4627 patients who 
underwent esophagectomy without adjuvant therapy either 
before or after surgery (esophagectomy alone) from 13 insti-
tutions was used to develop this new staging system. Unlike 
the previous staging system, the new AJCC staging system 
is not based on the anatomical extent (T, N, and M) alone 
but includes histopathologic type, biological activity (histo-
logic grade), and tumor location. Moreover, a revision of the 
N-classification from site-dependent to numerically based 
staging was also established.1 This renders the current AJCC 
staging system more reliable than previous editions.
The clinicopathologic presentations of esophageal can-
cer, including histology, tumor location, and age distribution 
are known to vary widely between patients in Eastern and 
Western countries.2,3 More than 50% of patients with esopha-
geal cancer are Chinese.4 However, Asian patients constitute 
only 25.2% (1168/4627) of the database used to elaborate the 
seventh edition of the AJCC staging system for esophageal 
cancer. Because squamous cell carcinoma is the most common 
pathologic type of esophageal cancer in the East, we believe 
that more data from Chinese patients should be assembled to 
evaluate the new staging system. This may create a more highly 
predictive staging system with widespread applicability.
In the current study, we present data from 2011 patients 
with esophageal squamous cell carcinoma (ESCC) who 
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underwent surgical resection alone from a single cancer center 
at the southeast of China. The data were used to evaluate the 
new AJCC staging system for ESCC and to clarify whether it 
adequately reflects prognosis.
PATIENTS AND METHODS
Patient Population
This study was undertaken at the Cancer Hospital of 
Shantou University Medical College and was approved by the 
Ethics Committee of that hospital. Since January 1995, out-
come data for all patients with esophageal cancer undergoing 
surgical resection were collected prospectively and stored in 
a database by data managers. Patients were followed with a 
clinical examination every 3 months for the first year, every 
6 months for the second year, and every 6–12 months there-
after. Between January 1995 and June 2010, 3375 cases with 
esophageal cancer were entered into this database. All opera-
tions were performed or closely supervised by two senior sur-
geons (Y.C. and J.Y.). For this study, only the patients with 
a histopathologic diagnosis of ESCC with no adjuvant treat-
ment either before or after surgery (esophagectomy alone) 
were evaluated. Tumors were staged according to the seventh 
edition of the AJCC staging system for ESCC. N-category 
was also classified by the extent of lymph node (LN) metasta-
sis (N0 = no LN metastasis; N1 = thoracic or abdominal LN 
metastasis; N2 = thoracic and abdominal LN metastasis).
Surgical Procedure
By means of a left or right thoracotomy, a surgical 
resection of a transthoracic en bloc esophagectomy with an 
end-to-side esophagogastric anastomosis was performed. The 
thoracotomy was usually performed on the left for tumors 
located below the aortic arch and on the right for tumors 
located above the aortic arch. One thousand eight hundred 
and two patients (89.6%) underwent a left thoracotomy, and 
the remaining 209 underwent a right thoracotomy. The anasto-
mosis was constructed in the neck through a separate cervical 
incision in 1948 patients (96.9%) and the upper chest in 63 
patients. In all patients, a standard abdominal lymphadenec-
tomy (left and right paracardial regions, along the lesser curve 
and the left gastric artery) and mediastinal lymphadenectomy 
(subcarinal, left and right bronchial, lower posterior medias-
tinum, pulmonary ligament, and paraesophageal and thoracic 
duct) was performed. For patient who underwent a right tho-
racotomy, the paratracheal, left, and right recurrent laryngeal 
nerve LNs were also dissected. Cervical lymphadenectomy 
was not systematically undertaken.
Statistical Analysis
Statistical analysis was performed using SPSS 13.0 
software (SPSS Inc., Chicago, IL, USA). Overall survival 
time was calculated from the date of operation to the date 
of death or most recent follow-up. Univariate analysis of 
survival was performed using the Kaplan–Meier method to 
estimate survival probabilities in patient subgroups and the 
log-rank test for statistical comparisons. Multivariate analy-
sis was performed to investigate the prognostic factors by the 
Cox proportional hazard regression model, with the entry 
factors of gender, age (≤60 versus >60 years), tumor length 
(≤5 versus >5 cm), histologic grade, R-category, pT category, 
pN category, pM category, pTNM stage, and the extent of 
LN metastasis. All statistical tests were performed two sided, 
and a p value less than 0.05 was considered to be statistically 
significant.
RESULTS
Patient Characteristics
Three thousand three hundred and seventy-five esopha-
gectiomies for esophageal cancer were performed between 
January 1995 and June 2010. Of these, 3181 were histopath-
ologically diagnosed as ESCC. Of these histologically con-
firmed diagnoses, 2047 did not receive adjuvant chemotherapy 
or radiotherapy either before or after surgery (esophagectomy 
alone). Thirty-six patients had to be excluded because of the 
lack of follow-up data, leaving a study group of 2011 patients 
(Fig. 1).
There were 1456 men and 555 women with a median 
age of 55 years (range, 30–82 years). The primary lesions 
were most often found in the middle third of the thoracic 
esophagus and had a median length of 5.0 cm (0.5–15.0 cm). 
An R0 resection (complete tumor resection) was achieved in 
1865 patients (92.7%), R1 (microscopically positive margins) 
in 83 patients (4.1%), and R2 (gross positive residual margins 
or M1 disease) in 63 patients (3.1%). The overall postopera-
tive 30-day mortality was 1.2% (24/2011). Hospital mortality 
rate was 1.5% (30/2011).
LN metastases were found in 875 patients (43.5%). 
A mean of 12.1 LNs (range, 4–44) was dissected from each 
specimen with a mean number of histologically positive LNs 
of 1.3.
Follow-Up
Follow-up was continued up to June 2011 or until 
death if this occurred earlier. The mean follow-up was 49.6 
months (range, 1–185 months). Seventy-two patients were 
lost to follow-up (3.6%). The 1-, 3-, and 5-year overall sur-
vival rates were 83.5, 57.4, and 47.4%, respectively, with a 
median survival time of 51.0 months (95% confidence inter-
val: 43.8–58.2).
Prognostic Factors
The distribution of the tumors according to the clini-
copathologic characteristics and tumor stage of the seventh 
edition of the AJCC staging system for ESCC is shown in 
Tables 1 and 2. The variables related to survival were gen-
der, age, tumor length, histologic grade, R-category, pT cat-
egory, pN category, pM category, pTNM stage, and extent of 
LN metastasis (p < 0.05). Tumor location did not influence 
survival (p = 0.723). In a separate subgroup analysis, the sur-
vival differences were not distinctive for the pN2 versus the 
pN3 category (p = 0.159; Fig. 2A) and stages IA versus IB 
(p = 0.922).
The pT1N0M0 cancers were subdivided into two groups 
by histologic grade in the new staging system: pT1N0M0G1 
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Total number 
n=3375 
Other histopathologic type
n=194
Adjuvant therapy n=829 
Adjuvant chemotherapy n=32 
Adjuvant radiotherapy n=645 
Adjuvant chenmoradiation n=152 
Neoadjuvant therapy n=305 
Neoadjuvant chemotherapy n=6 
Neoadjuvant radiotherapy n=193 
Neoadjuvant chenmoradiation n=106 
Lack of any follow-up data
n=36
n=3181 
n=2876 
n=2047 
Study group
n=2011
FIGURE 1.   Patients with esophageal cancer underwent surgical resection in the Cancer Hospital of Shantou University Medical 
College between January 1995 and June 2010.
TABLE 1.  Univariate Analysis for the Prognosis of 2011 Patients with Esophageal Squamous Cell Carcinoma According to 
Patient and Tumor Characteristics
Variable No. of patients (%) Median survival (mo)
Survival (%)
p Value1 yr 3 yr 5 yr
Gender 0.003
 Male 1456 (72.4) 47.0 82.8 56.1 45.4
 Female 555 (27.6) 74.0 85.5 60.7 52.6
Age (yr) <0.001
 ≤60 1324 (65.8) 61.0 84.7 59.6 50.2
 >60 687 (34.2) 42.0 81.3 53.1 42.2
Tumor location 0.723
 Upper third 231 (11.5) 47.0 83.7 54.2 48.5
 Middle third 1468 (73.0) 50.0 83.7 57.5 46.7
 Lower third 312 (15.5) 61.0 82.2 58.9 50.1
Tumor length <0.001
 ≤5 cm 1213 (60.3) 61.0 87.3 61.3 50.0
 >5 cm 798 (39.7) 42.0 77.7 51.4 43.5
Histologic grade <0.001
 Well (G1) 649 (32.3) 97.0 88.3 68.4 59.3
 Moderate (G2) 1119 (55.6) 44.0 83.0 54.5 44.2
 Poor (G3) 243 (12.1) 24.0 72.8 40.4 30.3
R-category <0.001
 R0 1865 (92.7) 62.0 85.8 60.7 50.7
 R1 83 (4.1) 15.0 66.6 22.7 13.0
 R2 63 (3.1) 11.0 38.1  6.3  0.0
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FIGURE 2.   Kaplan–Meier curves for overall survival according to different classification of N-category. (A) Classification of 
N-category according to the seventh edition of the AJCC staging system. No significantly survival differences were not observed 
for pN2 versus pN3 category (p = 0.159). (B) Classification of N-category according to the modified nodal categories of Yang et 
al.2: N0 (no positive LN), N1 (one positive LN), N2 (2–3 positive LNs), and N3 (≥4 positive LNs). The survival differences were 
distinctive (p < 0.001). (C) Classification of N-category according to the extent of lymph node metastasis: N0 = no LN metas-
tasis; N1 = thoracic or abdominal LN metastasis; N2 = thoracic and abdominal LN metastasis. The survival differences were 
distinctive (p < 0.001).
TABLE 2.  Univariate Analysis for the Prognosis of 2011 Patients with Esophageal Squamous Cell Carcinoma According to the 
Seventh Edition of AJCC Staging System for TNM Classification
Variable No of patients (%) Median survival (mo)
Survival (%)
p Value1 yr 3 yr 5 yr
pT category <0.001
 pTis 32 (1.6) – 100.0 100.0 100.0
 pT1a 57 (2.8) – 100.0 98.0 91.9
 pT1b 97 (4.8) – 97.9 80.0 67.2
 pT2 541 (26.9) 82.0 90.0 68.8 55.4
 pT3 1114 (55.4) 41.0 81.4 52.3 43.2
 pT4a 116 (5.8) 20.0 70.5 30.7 24.8
 pT4b 54 (2.7) 10.0 38.9 4.9 0.0
pN category <0.001
 pN0 1136 (56.5) 155.0 91.6 72.0 61.1
 pN1 496 (24.7) 33.0 79.8 45.8 36.6
 pN2 293 (14.6) 19.0 67.7 29.4 20.7
 pN3 86 (4.3) 14.0 52.7 26.4 20.0
pM category <0.001
 pM0 1988 (98.9) 52.0 83.9 58.0 48.0
 pM1 23 (1.1) 12.0 47.8 4.3 0.0
pTNM Stage <0.001
 0 32 (1.6) – 100.0 100.0 100.0
 Ia 73 (3.6) – 97.3 91.9 84.8
 Ib 107 (5.3) – 99.1 87.6 78.6
 IIa 360 (17.9) – 93.0 77.1 66.5
 IIb 619 (30.8) 73.0 90.9 65.8 53.4
 IIIa 418 (20.8) 31.0 78.6 43.2 33.6
 IIIb 196 (9.7) 18.0 67.5 29.6 22.4
 IIIc 183 (9.1) 14.0 55.4 21.2 15.0
 IV 23 (1.1) 12.0 47.8 4.3 0.0
Extent of LN metastasis <0.001
 N0 1136 155.0 91.6 72.0 61.1
 N1 578 32.0 79.8 45.7 36.6
 N2 297 17.0 60.0 24.1 16.2
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for stage IA and pT1N0M0G2–3 for stage IB. However, 
prognostic stratification could not be reproduced in our patient 
cohort. No difference in survival was noted between patients 
with pT1N0M0G1 and pT1N0M0G2–3 (p = 0.482; Fig. 3A). 
To find a distinctive classification, we subdivided pT1N0M0 
cancers according to tumor location and depth of infiltration. 
Tumor location did not influence survival in patients with 
pT1N0M0 cancers (p = 0.561; Fig. 3B). But significant 
differences were observed with subdivisions by depth of 
infiltration. Infiltration in the series was defined as limited to 
the mucosa (pT1a) tumors versus infiltration of the submucosa 
(pT1b). Patients with pT1aN0M0 had a significantly better 
outcome than that with pT1bN0M0 (P=0.010; Fig. 3C). When 
modified, the subdivisions of stage I patients in our cohort 
according to our findings: stage IA (pT1aN0M0) and stage IB 
(pT1bN0M0, pT2-3N0M0G1 with tumor locating at the lower 
third esophagus), the survival difference was also distinctive 
for stage IA versus IB (p = 0.047). It would seem from the 
findings from our cohort that subdivisions by depth of 
infiltration rather than histologic grade for pT1N0M0 cancers 
may better represent survival advantage.
In a recent study, Yang et al.2 suggested that the nodal 
categories for Chinese population with ESCC should be more 
accurately classified into four groups: N0 (no positive LN), 
N1 (1 positive LN), N2 (2–3 positive LNs), and N3 (≥4 posi-
tive LNs). When classifying our patients by these modified 
nodal categories, the survival differences were distinctive 
(p < 0.001), and in a subgroup analysis, a statistically sig-
nificant difference in survival was also found in pN2 ver-
sus pN3 category (p = 0.003; Fig. 2B). We also found that 
classification of N-category according to the extent of LN 
metastasis was effective in predicting survival in our study 
(p < 0.001; Fig. 2C).
To identify independent prognostic factors predicting 
survival after surgery for cancer, Cox regression analysis was 
performed. The results are presented in Table 3. Age, histologic 
grade, R-category, pT category, pN category, pM category, 
pTNM stage, and extent of LN metastasis were independent 
prognostic factors (p < 0.05). Gender and tumor length were 
not significantly correlated with survival (p > 0.05).
DISCUSSION
We report one of the largest ever single-center patient 
cohorts undergoing surgical resection alone for ESCC to date 
and evaluate the efficacy of the seventh edition of the AJCC 
staging system for ESCC. The identification of age, histologic 
grade, R-category, and AJCC stage as independent prognostic 
factors in our patient cohort support the findings of previous 
reports.1,5–8
The goal of a staging system is to have broad predictive 
power. Previous stage groupings of esophageal cancer 
were based on a simple, orderly arrangement of increasing 
anatomical T, then N, and then M classification. These 
groupings were not consistent with data or cancer biology. 
At the request of the AJCC, worldwide data were assembled 
to develop the seventh edition of the staging system for 
esophageal cancer. Histopathologic cell type, biological 
activity (histologic grade), and tumor location were added for 
stage grouping in this new system. Moreover, the new staging 
system presented a great improvement over previous editions 
for N-staging by grouping patients according to different 
numbers of metastatic LNs. But our data do not support 
the importance of grouping by location as performed in the 
AJCC staging system. Tumor location was not significantly 
correlated with survival in our study population.
The number of metastatic LNs was one of the most 
important independent prognostic factors for patients with 
esophageal cancer after curative resection.2 Before the seventh 
edition of the AJCC staging system for esophageal cancer 
was developed, many studies had examined the relationship 
between the number of positive LNs and overall survival6,9–17 
and tried to obtain an optimal cutoff point. Wijnhoven et al.6 
used a special statistical method to determine the optimal cut-
off points for the number of positive LNs. In their study, they 
subdivided pN-stage into three groups based on the number of 
positive LNs (0, 1–2, and ≥3 nodes positive). Mariette et al.16 
adopted a different cutoff of the number of positive LNs (0, 
1–4, and >4 nodes positive). Bollschweiler et al.13 found an 
optimal cutoff point between patients with one to five involved 
LNs and patients with greater than five LN metastases. 
Although they all revealed significant differences in prognosis 
FIGURE 3. A, Kaplan-Meier curves for overall survival of pT1N0M0 cancers subdivided by histologic grade (pT1N0M0G1 
 versus pT1N0M0G2-3). No significant difference in survival was observed (P = 0.482). B, Kaplan-Meier curves for overall survival 
of pT1N0M0 cancers subdivided by tumor location (Upper third versus Middle third versus Lower third). No significant differ-
ence in survival was observed (P = 0.561). C, Kaplan-Meier curves for overall survival of pT1N0M0 cancers subdivided by depth 
of infiltration (pT1aN0M0 versus pT1bN0M0). The survival difference was significant (P = 0.010). 
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between different groups, the small number of patients in their 
studies was a hindrance to detailed analysis.
A database of 4627 esophagectomy patients from 13 
institutions was used to develop the seventh edition of the 
AJCC staging system. The N-classification was divided into 
four groups: N0 (no positive LN), N1 (1–2 positive LNs), 
N2 (3–6 positive LNs), and N3 (≥7 positive LNs). The large 
sample size provided sufficient power to detect the relatively 
small survival difference between groups, making it superior 
to previous studies.
However, two recent studies from Chinese populations 
with ESCC suggested that there were no differences in sur-
vival between pN2 and pN3 patients,2,18 and we had achieved 
the same result in our study. Yang et al.2 suggested that the 
nodal categories for Chinese population with ESCC should 
be more accurately classified into four groups: N0 (no posi-
tive LN), N1 (1 positive LN), N2 (2–3 positive LNs), and N3 
(≥4 positive LNs). Our data supported these modified nodal 
categories. All of these data were assembled from a Chinese 
population with ESCC. The reasons for the difference in sur-
vival factors between Chinese patients and patients from the 
AJCC require further study. We suggest that more data from 
other institutions should be assembled to examine this finding.
All of our patients underwent two-field lymphadenec-
tomy. The N-category was also classified by the extent of LN 
metastasis in our study: N0 = no LN metastasis, N1 = one-
field LN metastasis (chest or abdomen), and N2 = two-field 
LN metastasis (chest and abdomen). Significant differences 
in survival were observed between different groups. Two-field 
LN metastases was a predictor of poor survival in patients 
with ESCC. The classification of N-category according to the 
extent of LN metastasis was easy and also effective in pre-
dicting survival in our study. But whether it is superior to the 
existing staging system needs further studies.
In the new AJCC staging system, pT1N0M0 cancers were 
subdivided into two groups by histologic grade: pT1N0M0G1 
to stage IA and pT1N0M0G2–3 to stages IB. We, however, did 
not note a significant difference in survival between these two 
groups. On the other hand, our data showed that patients with 
mucosal (pT1a) tumors had a significantly better outcome than 
tumors infiltrating the submucosa (pT1b) (5-year survival rate: 
91.9 versus 67.2%). This could be due to the different risk of 
LN metastases in pT1a and pT1b tumors (1.8 versus 17.5%). 
Moreover, subdivisions of pT1N0M0 cancers according to 
depth of infiltration had a significant impact on survival with 
pT1aN0M0 tumors having a significantly better outcome than 
those with pT1bN0M0. This finding is similar to those of many 
previous reports.6,8,10,19,20 It seems that subclassification of 
pT1N0M0 cancers by depth of infiltration may correlate better 
with the survival advantage of ESCC than histologic grade.
Finally, our data did not support the AJCC stage group-
ing adding tumor location. Tumor location was not signifi-
cantly correlated with survival in our study population (p = 
0.732). This result is similar to the report of Gertler et al.8
Our study has some limitations. First, the relatively 
small patient numbers in some subgroups may limit statisti-
cal power, such as the subgroup analysis of the pN2 versus 
pN3 categories. Second, it is a single-institution, retrospec-
tive study. It is difficult to establish an identical cutoff point 
for positive LNs in different research centers because of dif-
ferent surgical procedures (transhiatal, two- or three-field 
lymphadenectomy) in each center or the variant numbers 
of LNs resected from each patient. A good staging system 
should have a widespread applicability. It seems reasonable 
TABLE 3.  Multivariate Cox Regression Analysis for the 
Prognosis of 2011 Patients with Esophageal Squamous Cell 
Carcinoma
Prognostic factor Hazard ratio 95% CI p Value
Gender 0.105
 Male 1
 Female 0.889 0.770–1.025
Age (years) <0.001
 ≤60 1
 >60 1.772 1.680–1.875
Tumor length 0.097
 ≤5 cm 1
 >5 cm 1.116 0.980–1.271
Histologic grade <0.001
 Well (G1) 1
 Moderate (G2) 1.655 1.535–1.802
 Poor (G3) 2.740 2.621–2.883
R-category <0.001
 R0 1
 R1 1.284 1.202–1.399
 R2 2.432 2.290–2.642
pT category <0.001
 pTis 1
 pT1 1.099 1.022–1.453
 pT2 2.464 2.258–2.833
 pT3 3.558 3.420–3.742
 pT4 4.667 4.532–4.836
pN category <0.001
 pN0 1
 pN1 1.453 1.320–1.642
 pN2 2.640 2.485–2.844
 pN3 3.834 3.631–4.103
pM category <0.001
 pM0 1
 pM1 1.526 1.251–2.347
pTNM Stage 0.006
 0 1
 I 1.116 1.015–1.562
 II 2.705 2.315–3.578
 III 3.165 2.633–4.144
 IV 4.587 3.936–5.689
Extent of LN metastasis <0.001
 N0 1
 N1 1.575 1.428–1.776
 N2 2.691 2.569–2.835
CI, confidence interval.
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to believe that a multi-institutional collaborative study with 
a large cohort could achieve a more convincing result. Third, 
the number of LNs resected from each patient in our study is 
limited (mean: 12.1 per case). Most of our patients underwent 
a left thoracotomy. The common hepatic nodes, celiac nodes, 
and upper right mediastinal nodes were difficult to remove 
through this operative route. Increasing the extent of lymphad-
enectomy could provide more accurate pathologic N-staging. 
However, the extent of lymphadenectomy should be balanced 
against the risk of complications. Current criteria recommend 
taking as many LNs as possible. Schwarz and Smith21 used 
multivariable proportional hazard analysis of the Surveillance, 
Epidemiology and End-Results data of 5620 esophagecto-
mies and recommended resecting at least 13 LNs. Peyre et 
al.22 used logistic and Cox regression analysis of an interna-
tional database of 2303 esophagectomies and recommended 
that a minimum of 23 LNs should be removed to maximize 
the survival benefit. Rizk et al.23 used Worldwide Esophageal 
Cancer Collaboration data to define the optimum lymphad-
enectomy and recommended that to maximize 5-year survival, 
a minimum of 10 nodes should be resected for T1 cancer, 20 
nodes for T2 cancer, and 30 or more nodes for T3/T4 cancers. 
Nonetheless, the extent of lymphadenectomy and its effect on 
improving survival are still debated.
In conclusion, the seventh edition of the AJCC staging 
system is appropriate for ESCC with an acceptable predic-
tive capability. However, tumor location is not significantly 
correlated with survival in our study, and the subdivisions of 
pT1N0M0 cancers and the N-classification may need to be 
modified. Further studies are required to confirm these results.
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